Bausch + Lomb (NYSE:BLCO) Price Target Lowered to $12.00 at Morgan Stanley

Bausch + Lomb (NYSE:BLCO - Free Report) had its price objective decreased by Morgan Stanley from $18.00 to $12.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

A number of other research firms also recently issued reports on BLCO. HC Wainwright cut their target price on shares of Bausch + Lomb from $20.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Citigroup dropped their target price on Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating on the stock in a research report on Thursday, May 1st. Stifel Nicolaus lowered their target price on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a research report on Thursday, April 3rd. Royal Bank of Canada decreased their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, April 4th. Finally, Wells Fargo & Company dropped their price target on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, Bausch + Lomb presently has an average rating of "Hold" and an average target price of $15.50.

Bausch + Lomb Stock Down 2.3 %

Shares of BLCO stock traded down $0.27 during trading on Tuesday, hitting $11.23. 657,304 shares of the company were exchanged, compared to its average volume of 649,977. The business's 50-day simple moving average is $13.45 and its 200 day simple moving average is $16.57. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60. Bausch + Lomb has a twelve month low of $10.45 and a twelve month high of $21.69. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of -12.34, a P/E/G ratio of 0.85 and a beta of 0.58.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.10). The business had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.15 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The company's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.07 earnings per share. As a group, analysts forecast that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Bausch + Lomb

Institutional investors have recently bought and sold shares of the company. Blue Trust Inc. boosted its position in shares of Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after purchasing an additional 1,004 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of Bausch + Lomb during the fourth quarter worth about $72,000. Commonwealth Equity Services LLC acquired a new position in Bausch + Lomb in the 4th quarter valued at $181,000. Alpine Global Management LLC purchased a new stake in shares of Bausch + Lomb in the fourth quarter valued at approximately $181,000. Finally, Covestor Ltd purchased a new position in Bausch + Lomb in the fourth quarter valued at about $188,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.